In the heart of Toronto, a Canadian researcher, Daniel Drucker, and his team are pushing the boundaries of medical science, building upon their groundbreaking discovery that led to the development of Ozempic. But their journey is far from over, as they continue to unravel the mysteries behind this remarkable drug's success.
The Power of Ozempic:
Ozempic, a member of the glucagon-like peptide-1 receptor agonists (GLP-1s) family, has already proven its mettle in blood sugar control and weight loss. But its potential extends far beyond these initial applications. Study after study reveals its ability to reduce the risk of strokes, heart attacks, kidney and liver diseases, sleep apnea, and even arthritis. But what's the secret behind its versatility?
Unraveling the Mystery:
Dr. Drucker, a senior investigator at the Lunenfeld-Tanenbaum Research Institute, explains that the answer is complex. Some benefits of GLP-1 medicines are independent of blood sugar control and weight loss. For instance, patients taking semaglutide (Ozempic for Type 2 diabetes or Wegovy for weight loss) can experience improved liver health, even without significant weight loss. This intriguing phenomenon sparks curiosity about the drug's mechanisms.
The Lab's Quest:
Dr. Drucker's lab, a hub for GLP-1 research in Canada, is dedicated to understanding these mechanisms. They explore how these drugs affect chronic inflammation and prevent kidney disease. The team's work is particularly significant as cheaper generic versions of Ozempic are set to hit the Canadian market this year, potentially sparking a frenzy.
A Reptilian Connection:
The story takes an unexpected twist with the involvement of a reptile. In the mid-1990s, Dr. Drucker, inspired by an American scientist's discovery of a reptile GLP-1-related molecule, obtained a Gila monster, a lizard native to the deserts of the southern U.S. and Mexico, from the Royal Ontario Museum. He analyzed its venom and cloned the reptile genes for GLP-1 and exendin-4, a peptide that acts on GLP-1 receptors and is more stable than its human counterpart. This discovery, published in 1997, paved the way for short-acting GLP-1s for diabetes and, eventually, the long-acting Ozempic.
A Tribute to the Lizard:
Dr. Drucker's appreciation for the Gila monster is evident in his office, where a bottle of Gila brand tequila sits, and in his lab's freezer, where the original monster's body is lovingly preserved. This reptile has also inspired Chi Kin Wong, a postdoctoral scientist in the lab, who got a tattoo of the Gila monster after his study revealed that semaglutide directly acts on immune cells to reduce inflammation.
Inflammation and Beyond:
Dr. Wong's follow-up study showed that semaglutide acts on GLP-1 receptors in the brain, reducing inflammation throughout the body. This is particularly intriguing as GLP-1 receptors are not widely found on immune cells outside the gut. The implications are significant, as these drugs are being studied for treating inflammatory diseases like rheumatoid arthritis.
The Ozempic Enigma:
The question of where and how GLP-1 receptors are active is crucial to understanding Ozempic's mechanism. While it's known that the drug acts on cells in the pancreas and brain, where GLP-1 receptors are abundant, finding these receptors elsewhere is like searching for Waldo. Maria Jesus Gonzalez-Rellan, a researcher in Dr. Drucker's lab, has been investigating this puzzle in the context of liver function. She found that GLP-1 receptors are present on specialized endothelial cells in the liver's blood vessels, and their absence can diminish the drug's benefits.
Beyond Weight Loss:
The research highlights that weight loss is not the sole factor in the drug's success. Dr. Drucker emphasizes that these findings are not just academic; they can guide medical scientists and pharmaceutical companies in designing better Ozempic derivatives or understanding why GLP-1s don't seem to work for Parkinson's or Alzheimer's, as initially hoped.
A Personal Connection:
Rola Hammoud, another postdoctoral scientist in the lab, shares a personal connection with the research. As a dietician in Lebanon before Ozempic, she witnessed patients struggling with weight loss, often blaming themselves. Now, she studies the gut hormone GIP, which works with GLP-1 in tirzepatide, highlighting the complex physiological processes involved in weight loss and appetite control.
The Future of GLP-1s:
As the world awaits the arrival of generic Ozempic, the research continues to evolve. The team's work is not just about understanding the past but also shaping the future of these powerful drugs. But here's where it gets controversial: are these drugs a panacea for all health issues, or should we be cautious about their widespread use? The debate is open, and the research community eagerly awaits your thoughts.
